Form 4: Cormorant Asset Management Increases Stake in Corbus Pharmaceuticals Holdings

Cormorant Asset Management, LP, along with related entities and Bihua Chen, reported purchasing additional shares of Corbus Pharmaceuticals Holdings, Inc. on September 20, 2024, increasing their beneficial ownership.

Summary

• On September 20, 2024, Cormorant Asset Management, LP, Cormorant Global Healthcare Master Fund, LP, and Bihua Chen collectively purchased shares of Corbus Pharmaceuticals Holdings, Inc.
• The purchases were made through a series of open market transactions at varying prices.
• The weighted average purchase prices ranged from $17.475 to $22.228 per share.
• The total number of shares beneficially owned following these transactions is 2,375,000.
• Cormorant Asset Management, LP serves as the investment manager of Cormorant Global Healthcare Master Fund, LP.
• Cormorant Global Healthcare GP, LLC serves as the General Partner of the Master Fund, and Bihua Chen serves as manager of Cormorant, GP LLC.
• The reporting persons disclaim beneficial ownership of the shares except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the increased investment by a significant shareholder, suggesting confidence in the company's future. However, it's important to consider this information in the context of the company's overall financial health and industry trends.

Positives

• Increased investment by Cormorant Asset Management could signal confidence in Corbus Pharmaceuticals' future prospects.
• The purchases were made at increasing prices, suggesting a growing belief in the company's value.

Management Comments

• The Reporting Persons undertake to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
• Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or significant shareholders of a publicly traded company buy or sell shares. This filing indicates increased investment by a major shareholder, which can be viewed as a positive signal, but should be considered alongside other factors when evaluating the company's prospects.

Comparison to Industry Standards

• Comparing Cormorant's investment activity to other healthcare-focused funds like Orbimed or RA Capital Management could provide context.
• Analyzing similar Form 4 filings for comparable companies in the pharmaceutical sector can reveal trends in insider sentiment.
• The size of the stake (2,375,000 shares) should be compared to the total outstanding shares of Corbus Pharmaceuticals to assess the significance of Cormorant's position.

Stakeholder Impact

• Shareholders may view the increased investment positively, potentially leading to a short-term increase in stock price.
• The increased stake could provide Corbus Pharmaceuticals with more stability and resources.

Key Dates